Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06605625 · ClinicalTrials.gov registry record
Vaccine Responses in Cancer
A clinical trial of Viral Vaccines, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 250
- Enrollment target
- 1
- Study location
NCT06605625 is a study of Viral Vaccines that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 250 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06605625, a study of Viral Vaccines, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 250 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
Conditions Studied
Interventions
- BIOLOGICAL Influenza vaccination
- BIOLOGICAL SARS-CoV-2 vaccine
- BIOLOGICAL Zoster Vaccine Recombinant
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-11-04 |
| Est. Completion | 2028-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06605625
The ClinicalTrials.gov registry entry for NCT06605625 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Viral Vaccines appearing as the primary indexed condition, and to 3 interventions - of which Influenza vaccination is the first listed.
NCT06605625 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06605625 about?
NCT06605625 is a clinical study titled "Vaccine Responses in Cancer". The investigators are conducting a prospective unblinded study of individuals diagnosed with cancer who will receive one or more of the following: influenza, SARS-CoV2 and shingles.
What is the current status of trial NCT06605625?
This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2022-11-04. Estimated completion is 2028-10.
What conditions does trial NCT06605625 study?
This clinical trial studies the following conditions: Viral Vaccines.
What interventions are being tested in trial NCT06605625?
The interventions under investigation include: Influenza vaccination (BIOLOGICAL), SARS-CoV-2 vaccine (BIOLOGICAL), Zoster Vaccine Recombinant (BIOLOGICAL).
Who is sponsoring clinical trial NCT06605625?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06605625 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Viral Vaccines
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.